Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-deoxy-1-methoxycarbamido-beta-D-glucopyranose is a synthetic small molecule belonging to the class of hexoses, specifically a β-D-glucopyranosylamine analog. It has been studied as an experimental inhibitor of glycogen phosphorylase, particularly the muscle form (PYGM), which plays a key role in carbohydrate metabolism by catalyzing the breakdown of glycogen. Inhibition of this enzyme is being explored as a potential strategy for controlling hepatic glycogenolysis and managing hyperglycemia. The compound binds at the catalytic site of glycogen phosphorylase, forming direct and water-mediated hydrogen bonds with key residues and inducing minor conformational changes in the enzyme[1][5][7]. Its development status remains experimental.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-deoxy-1-methoxycarbamido-beta-D-glucopyranose.